First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.

First-line durvalumab therapy alone or in combination with tremelimumab for metastatic head and neck squamous cell carcinoma: A cost-effectiveness analysis.

<h4>Objective</h4>In patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), the KESTREL study evaluated durvalumab with or without tremelimumab, as well as the EXTREME regimen (platinum, 5-fluorouracil, and cetuximab). In the first-line treatment of R/M...

Full description

Saved in:
Bibliographic Details
Main Authors: Huijuan Li, Xueyan Liang, Shiran Qin, Xiaoyu Chen, Liju Huang, Yan Li
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0324057
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items